β 1 ‐ and β 2 ‐adrenoceptor responses in cardiomyocytes derived from human embryonic stem cells: comparison with failing and non‐failing adult human heart
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Background and purpose: Characterization of human embryonic stem cell‐derived cardiomyocytes (hESC‐CM) in relation to adult myocytes is essential for their future use in transplantation or as a model system. The β‐adrenoceptor pathways, which are known to be effective early in hESC‐CM development, are of major importance because of their control of rate and force of beating, arrhythmia generation and apoptosis/necrosis. We have therefore performed detailed pharmacological analysis of the β‐adrenoceptor responses in developing hESC‐CM. Experimental approach: hESC‐CMs were differentiated from H7 ESCs and studied up to 79 days of differentiation. Rate of beating and time course of contraction and relaxation were measured in superfused preparations. Key results: Responses to the mixed β 1 ‐ and β 2 ‐adrenoceptor agonist isoprenaline were evident from day 10 to day 79. Stability of the responses during an application, for repeated applications on the same experimental day and over the time of development, was determined. Concentrations for half‐maximal response (12.9 n M ) were similar to those from adult human heart, but closer to those obtained from failing rather than normal ventricle. Acceleration of both contraction and relaxation was quantitatively similar to that in adult ventricular myocytes, as was sensitivity to muscarinic inhibition. Use of specific antagonists showed that both β 1 ‐ and β 2 ‐adrenoceptors contributed to contractile responses, as seen with adult myocytes. Conclusions and implications: These data show the compatibility of hESC‐CM with adult human myocardium in terms of β‐adrenoceptor response. The experiments described here also confirm the utility of the hESC‐CM preparation for detailed pharmacological analysis. British Journal of Pharmacology (2008) 153 , 751–759; doi: 10.1038/sj.bjp.0707619 ; published online 14 January 2008
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A fundamental aspect of myocardial function is the response to adrenergic agonists, which has been studied extensively in both rodents and humans, making β-adrenergic response a good test of the ability of our engineered ventricles to recapitulate normal cardiac pharmacology57,58.”
From A tissue-engineered scale model of the heart ventricle (2018) · cites this paper as [58]
Citations
Cites
Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts
Murry, C. E., Soonpaa, M. H., Reinecke, H., Nakajima, H., Nakajima, H. O., Rubart, M., Pasumarthi, K. B. S., Ismail Virag, J., Bartelmez, S. H., Poppa, V., et al. (2004) · Nature · doi:10.1038/nature02446 · Cited by 2,154
Kehat, I., Kenyagin‐Karsenti, D., Snir, M., Segev, H., Amit, M., Gepstein, A., Livne, E., Binah, O., Itskovitz‐Eldor, J., & Gepstein, L. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12131 · Cited by 1,814
Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium
Balsam, L. B., Wagers, A. J., Christensen, J. L., Kofidis, T., Weissman, I. L., & Robbins, R. C. (2004) · Nature · doi:10.1038/nature02460 · Cited by 1,736
Kehat, I., Kenyagin‐Karsenti, D., Snir, M., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci200112131 · Cited by 1,536
Mummery, C., Ward-van Oostwaard, D., Doevendans, P., Spijker, R., van den Brink, S., Hassink, R., van der Heyden, M., Opthof, T., Pera, M., de la Riviere, A. B., et al. (2003) · Circulation · doi:10.1161/01.cir.0000068356.38592.68 · Cited by 1,001
Characterization and Enrichment of Cardiomyocytes Derived From Human Embryonic Stem Cells
Xu, C., Police, S., Rao, N., & Carpenter, M. K. (2002) · Circulation Research · doi:10.1161/01.res.0000035254.80718.91 · Cited by 902
Electromechanical integration of cardiomyocytes derived from human embryonic stem cells
Kehat, I., Khimovich, L., Caspi, O., Gepstein, A., Shofti, R., Arbel, G., Huber, I., Satin, J., Itskovitz-Eldor, J., & Gepstein, L. (2004) · Nature Biotechnology · doi:10.1038/nbt1014 · Cited by 880
He, J.-Q., Ma, Y., Lee, Y., Thomson, J. A., & Kamp, T. J. (2003) · Circulation Research · doi:10.1161/01.res.0000080317.92718.99 · Cited by 800
What Is the Role of β-Adrenergic Signaling in Heart Failure?
Lohse, M. J., Engelhardt, S., & Eschenhagen, T. (2003) · Circulation Research · doi:10.1161/01.res.0000102042.83024.ca · Cited by 764
Brodde, O. E. (1991) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06662-1 · Cited by 572
Cited by
Concise Review: Maturation Phases of Human Pluripotent Stem Cell-Derived Cardiomyocytes
Robertson, C., Tran, D. D., & George, S. C. (2013) · Stem Cells · doi:10.1002/stem.1331 · Cited by 354
Immaturity of Human Stem-Cell-Derived Cardiomyocytes in Culture: Fatal Flaw or Soluble Problem?
Veerman, C. C., Kosmidis, G., Mummery, C. L., Casini, S., Verkerk, A. O., & Bellin, M. (2015) · Stem Cells and Development · doi:10.1089/scd.2014.0533 · Cited by 265
Maturing human pluripotent stem cell-derived cardiomyocytes in human engineered cardiac tissues
Feric, N. T., & Radisic, M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.04.019 · Cited by 247
A tissue-engineered scale model of the heart ventricle
MacQueen, L. A., Sheehy, S. P., Chantre, C. O., Zimmerman, J. F., Pasqualini, F. S., Liu, X., Goss, J. A., Campbell, P. H., Gonzalez, G. M., Park, S.-J., et al. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0271-5 · Cited by 227
Hayakawa, T., Kunihiro, T., Ando, T., Kobayashi, S., Matsui, E., Yada, H., Kanda, Y., Kurokawa, J., & Furukawa, T. (2014) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2014.09.010 · Cited by 198
Metadata
- Authors
- Brito‐Martins, M., Harding, S. E., & Ali, N. N.
- Affiliations
- Imperial College London (GB)
- Corresponding author
- Harding, S E
- ORCID
- Harding, S E
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2008-02
- Volume
- 153
- Issue
- 4
- Pages
- 751-759
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- PMC
- PMC2259205
- OpenAlex
- W2013721243
- Cited by
- 74
- References
- 31
- Citations by year
- 2025: 3 · 2024: 3 · 2022: 3 · 2021: 2 · 2020: 3 · 2019: 3 · 2018: 5 · 2017: 2 · 2016: 3 · 2015: 4 · 2014: 7 · 2013: 2 · 2012: 10
- FWCI
- 3.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- onlinelibrary.wiley.com/termsAndConditions#vor (vor, 363 d)
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm)
- Locations
- British Journal of Pharmacology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Centre for the Replacement, Refinement and Reduction of Animals in Research (G0600373/1)
- Biotechnology and Biological Sciences Research Council
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Phosphodiesterase function and regulation
- Keywords
- human embryonic stem cell-derived cardiomyocytes, beta1-adrenergic receptor, beta2-adrenergic receptor, isoproterenol, cardiomyocyte differentiation, beating frequency, heart failure, ventricular myocytes, adrenergic signaling
- MeSH terms
- Adrenergic beta-Agonists, Adrenergic beta-Antagonists, Adult, Animals, Carbachol, Cell Differentiation, Cell Line, Dose-Response Relationship, Drug, Heart Failure, Humans, Imidazoles, Isoproterenol, Myocardial Contraction, Propanolamines, Receptors, Muscarinic, Time Factors, Receptors, Adrenergic, beta-1, Receptors, Adrenergic, beta-2, Muscarinic Agonists, Cell Lineage, Myocytes, Cardiac, Stem Cell Transplantation, Mice, Embryonic Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: β 1 ‐ and β 2 ‐adrenoceptor responses in cardiomyocytes derived from human embryonic stem cells: comparison with failing and non‐failing adult human heart. https://app.cochat.ai/papers/10.1038/sj.bjp.0707619
- The paper
- Brito‐Martins, M., Harding, S. E., & Ali, N. N. (2008). β 1 ‐ and β 2 ‐adrenoceptor responses in cardiomyocytes derived from human embryonic stem cells: comparison with failing and non‐failing adult human heart. British Journal of Pharmacology. https://doi.org/10.1038/sj.bjp.0707619
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.